Render Target: STATIC
Render Timestamp: 2024-11-08T09:53:28.556Z
Commit: 3c1f305a63297e594ac8d7bb5424007d592d68be
XML generation date: 2024-04-05 20:47:54.048
Product last modified at: 2024-05-30T07:21:51.289Z
1% for the planet logo
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

SARS-CoV-2 ORF7a Antibody #67750

Filter:
  • WB

    Supporting Data

    REACTIVITY Vir
    SENSITIVITY Endogenous
    MW (kDa) 9-14
    SOURCE Rabbit
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • Vir-Virus 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    SARS-CoV-2 ORF7a Antibody recognizes endogenous levels of total SARS-CoV-2 ORF7a protein.

    Species Reactivity:

    Virus

    Source / Purification

    Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val74 of SARS-CoV-2 ORF7a protein. Antibodies are purified by protein A and peptide affinity chromatography.

    Background

    SARS-CoV-2 ORF7a is a type-I transmembrane protein with an amino-terminal immunoglobulin (IgG)-like domain involved in immune modulation and a short cytosolic tail that contains an endoplasmic reticulum (ER) retention motif that mediates trafficking to the ER-Golgi intermediate complex (ERGIC) (1). Studies of ORF7a in SARS-CoV identified roles in apoptosis and cell cycle progression (2-4). Regulation of apoptosis has been attributed to an association with Bcl-xL, a key pro-survival Bcl-2 family member (5). Studies in both SARS-CoV and SARS-CoV-2 have shown that ORF7a can promote viral release through inhibition of BST2 (6,7). There are also reports that SARS-CoV-2 contributes to immune regulation as part of the viral life cycle. It can inhibit type I interferon signaling through inhibition of STAT2 phosphorylation (8). However, it can also lead to activation of NF-κB and induce the expression of inflammatory cytokines (9). ORF7a has also been shown to inhibit late stages of autophagy by reducing lysosomal acidity (10).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.